Herein, we present a randomized phase III Italian-Canadian trial named TORCH (Tarceva or
Chemotherapy). In TORCH, we are investigating whether erlotinib as first-line therapy until …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …